Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Half the volume today agreed with you. The other half may live to regret it. Does Thursday still count as early in the week? Let's see what tomorrow brings.
ps. The little princess warrior will likely have to wait another year for her castle. For now, we wait as this process lingers on.
pps. Let's hope that all good things come to those who wait.
Dear Mr. Frank,
I would like to have a meeting with you that is unless you have something else planned.
Thanks.
CW
The funny thing with this stock is we are always waiting for that next PR. This will be the big one. The next one for sure. I am so confused right now that I don't think the next one is the big one. We are waiting to apply for a type "C" meeting. Then endpoint change and FDA approval is next. However, Revive will likely have to unblind the next 500 to get that so that may come first. Wash and scrub the data somewhere in there. Pay statistician and weekly check for Derrick Walsh et al. for doing whatever and tip the moving guy if that has even started yet. Did Revive get the $5,000,000? What happens if they don't get it? So confused that I will just sit back and wait for BF or MF to get this moving again.
I am a Star Wars Fan. My favorite is The Empire Strikes Back. The company that created the armor for the Stormtroopers should be fired. These uniforms provide them virtually no protection. They might as well wear a Tommy Bahama shirt with some Khakis. Also, it wouldn't hurt for them to undergo sme shooting lessons. They have aim like the Sleastacks from Land of the Lost.
ps. Still optimistic with Revive but lost a lot of money on paper. If I sold at $.72, I'd be retired. Anyway, maybe someday, sooner than later, things will turn around. If not, I need a second job. For now, I am focusing on work and trying not to think so much about this investment. Time will tell. I will not sell until I see the results of the next 500. GLTA, even the guys on here who lost their hope and the guy who hopes I end up living under a bridge.
Sure, it may be a pipe dream....but one day we may wake up and see Revive as part of this action. Not happy where we are,but at least, we have a chip and a chair. We need to unblind the rest of the trial and show BP the true potential of Revive. When the world see what this drug can do at higher doses, there is no reason, $RVVTF can't be next on the list.
https://health.economictimes.indiatimes.com/news/pharma/pfizer-partners-with-clear-creek-bio-to-develop-oral-covid-19-drug/96047877?action=profile_completion&utm_source=Mailer&utm_medium=newsletter&utm_campaign=ethealth_news_2022-12-08&dt=2022-12-08&em=Z2FyeS5mcmFka2luQHBhbG1iZWFjaHNjaG9vbHMub3Jn
The money is being used to scrub the remaining patient data in anticipation of EUA and initial cost to mass produce and market Bucillamine.. 750 patients is more than enough data for the trial. Also, one can hope this cover fees of moving to NASDAQ when the pps hits $4, costs of moving Revive to the states, some psychedelic money to appease Derrick Walsh and a new putter for Captain Sweatpants.
ps. Who knows?
pps. Let's see how the market reacts today. I'm done speculating with this stock. Cheers to $RVVTF rebounding after the holidays.
The dream of a 5,000,000,000 pill order with Suppria seems like a pipe dream at this point. A BP buyout works. Somebody other than fifteen of who post here must be interested in this gem.
ps. Not much to say these days as our retirement parties may be pushed back a bit.
Saw the post this morning. So sad. If one wants to sell, then be gone, but I venture to believe that this drug will eventually make it to market when the new data is unblinded. It is versatile, safe, and easy to mass produce. That has to be worth more than the few cents I am down.
ps. I clearly thought the Christmas presents would include some large ticket items this winter, but that will not be the case, GLTA as the saga continues.
Hopefully, buying 2,800,000 shares. What a sh-tshow today. One side of me wants this thing to end so I can move on and the other reminds me how much money I have wrapped up in this stuff. Better bring some big boys to the meeting, Michael Frank. Obviously, Revive is still around so the data must be good. I gather they will wash and clean another 500, with the higher dosage so numbers will look even better, and we will persevere.
I wish all his followers would buy 10,000 shares. It seems worth the risk for a few bucks. Maybe we hear next week about the endpoints.
GLTA
Even if the endpoints are approved, Revive still will likely need to submit 500 more patient's data. Then we wait for EUA. MF said he will go directly to the DSMB and try to sell it on the free market too. I am hoping for a quick jump on endpoint approval. I think that may make the rest of the waiting easier.
ps. If the endpoint change is not approved, one wonders what MF has up his sleeves. A third endpoint submission, I believe, is not likely unless the FDA gives him a pretty good idea what they are looking for in the end. I hope they already did this in round two.
pps. Like you said, one way or the other people are going to start buying or selling very soon.
Come on VERU boys. Keep buying. We have been sitting here for a while and your timing is good. We already have another 500 patients washed, scrubbed, and packaged. All we need is for the coach to put us in the game.
It may not be apples to apples but I have convinced myself that Veru was turned down at this point because the FDA sees something better.
Maybe some Veru boys will join us today. This may not make a difference in the long run, but I sure would like to see some green today.
We are still waiting for you to buy some more. Sheesh. There is no excitement or volume right now. I actually thought someone turned off my chat feature.
ps. We wait.
I think that guy sold half his shares today.
I heard an ad on the radio while driving home from work last night. It was for a drug that treated Rheumatoid Arthritis. I am quite sure you know it or even take it. Anyway, the point is that there were more than six million warnings and caveats at the end of the message that the announcer read so fast that I could barely make out irregular heartbeat and even death. With the multiple uses of Bucillamine as an antiviral and anti-inflammatory, this thing has to be worth more than $.19.
ps. I'm getting ready for another run.
pps. We wait.
This volume is laughable. Everyone is holding, but nobody is buying.
ps. We wait.
I'm not sure if I read this or dreamt it to be honest. But, if the second endpoint fails and we tank, will MF be so stubborn as not to try BMT suggested endpoint because of his ego and go straight to DMSB for unblinding and hopefully, OTC approval? He has to try a third time, right?
ps. Let's hope #2 makes it through and this thought is a moot point.
pps. We wait
I just read elsewhere that the FDA approved the exact same endpoints for another company with another drug. Let's see.
A better question to ask the longs here is what percent chance to we have of getting this thing approved on round two? Will there need to be a round three like BMT suggested with a variation in endpoint, will the trials be completely unblinded and if rejected, can Captain Sweatpants get this thing to market with DSMB nod? I've got about three more questions, but any taking a shot at the first will be much obliged.
ps. I say 25% and I'll take those odds. Chip and a chair and a fair chance is all I ask.
pps. Nobody really knows how much guidance Michael Frank had with the FDA before the second submission and how involved each doctor on our team was with the data so everything we read is speculative. My retirement is in the hands of MF.
ppps. I wonder where the u haul truck is right now.
Rick- I am trying to follow your logic. If this is true and who is to say if it is, how do you explain the new pr correcting the poorly worded one?
I read through the posts. I don't even know what to think anymore, but that fellow, Bobster, did a phenomenal job laying out his argument. I just don't know what is fact or fiction. It seems like the endpoints are simple, but we have to trust that MF knows what he is doing. Guys like him don't like to be wrong and then submit what a semi-credentialed BMT guy said all along. MF's ego would be crushed. MF must be pretty confident that this will go through. Me? I really don't know, but I will say this. Bucy works so someone will buy it for more than $.18 if RVVTF runs into a snag. Ready to brace for a drop if we have to resubmit but have accepted the fact that I will be holding longer than predicted.
ps. Can I get a "we wait"?
Looks like I am the first one up this morning heading to a backbreaking day at work Look for a boost this morning as MF updates Investor Deck and gets ready to sell some Bucillamine for Covid and flu relief.
https://revivethera.com/wp-content/uploads/2022/10/RVV-Deck-October-2022c.pdf
ps. Let's get em.
pps. Hey Blue- Check out Frankfort this morning.
No but the 52 week high.low differential is insane.
Yes. Buy more, lots more. I am tired of bleeding back to $.18. When will Revive draw blood?
ps. We wait.
pps Maybe I will grow a mustache to pass the time.
It's the conflict between what the endpoints should be in the trial. BMT and MF disagree and the Dales Report mentioned that this can be a risky investment without proper endpoints. It was the first negative thing that came out of them. MF basically told BMT, who he gave options, to be quiet. BMT has a loyal following and some have pulled back some shares I gather even though there is not evidence that BMT sold any. I actually believe he stated that he did not sell any. Anyway, it sounds like a soap opera and they need to let it go and stop with the petty comments back and forth. MF has the data and BMT does not. If the new endpoints of reducing two symptoms doesn't work out then if allowed by the FDA, they will go to oxygen saturation level which is what BMT wants them to do now, but clearly the data is heavy in the other direction.
ps. We wait.
Boys- I have quite a stack myself but the drop in price was likely due to the bickering between Captain Sweatpants and BMT. A fellow posted the last twenty or so trades of the day and they were overwhelmingly sell orders. In reality, the number of shares were quite small. One large buy could bring us back by 10:00 a.m.
I'd like to think the expert doctors have got a good plan, and I leave it to MF to carry us forward. Someone wrote the following, and it is appears to be quite true. The Polymerase Chain Reaction results must have been amazing and not trying to get through on that alone would be reckless. In other words, if we fail and later found out that the Polymerase Chain Reaction numbers were not submitted, and they didn't try to use them, we would think they are crazy.
ps. Not loving where we in pps but if things go south, I will just shut up and wait for psychedelics to get me even. oh yea- and work a few more years.
pps. Still have a chip and a chair but now we have a hard ten against a jack.
Sure as h-ll hope that cleaning up two symptoms even if a patient has five is good enough for approval.
ps. A little confused with the "Nobody" comment of BMT but the airplane example sure makes sense. Let's hope this thing takes flight soon.
Revive has a former FDA doctor on its side- a Doctor Boulevare if I remember correctly. Clearly, they relied on this individual to direct them with their endpoint adjustments. . Going against BMT does not make me happy, but if RVVT is "stacking the books" and picking Buccy's two best symptoms, so be it. Let's show the data and then if they want another endpoint, we can visit that .Hopefully, someone will take notice of the symptom reduction and we can move forward.
ps. If MF loves BMT so much to give him options, then he obviously values his opinion and to go against him, the data must be something special.
pps. Fingers crossed and hope the longs stay strong and the FDA comes to its senses.
My first reaction is that the pr was placed because he said if would be this week and saw the pps slipping earlier today because investors fled when no news was announced.
I see an endpoint change that BMT is not in 100% agreement with MF. This is concerning, but the stats as mentioned by others must be overwhelmingly positive that if those endpoints are acceptable, we are golden.
ps. We wait.
https://nationalpost.com/health/canada-covid-19-drug-merck-independent-trial
Affirmative, but I am giving the big guy an extra few days just to make sure his t's are crossed and his i's are dotted.
The timing for Revive is good. I have to imagine based on the 210 data and the progression of events that Health Canada and large pharmaceutical companies are watching closely and may have already been in contact with MF.
ps. With that said, hoping for a big news very soon.
Dear Michael Frank,
I believe we are at T minus 4 days. I look forward to hearing from you next week. You got this.
ps. Please double check the phrasing of your pr's. Let keep it clear and concise like your last one.
Dear Mr. Frank,
This is a reminder that we are at T minus 5 days. Thanks.
Dear Michael Frank,
I am just checking in to make sure that you saw my prior post and that we are on the same page.
T minus 6 days to new pr detailing plans for submission to FDA and DSMB meeting agenda.
If we are good, please do not reply to this post. Thanks.
ps. Let's go!!
pps. Three babies needs some money for college tuition. Let's make this happen.
Let's get em. I give our boy eight working days at maximum to a have a kick a$$ pr detailing the next step. Stay locked and loaded. Wow. I haven't thought f that in a long time, but this time the end is near.
I like "Submission of revised protocol next week." The specific timetable is now out there. Now, let's meet it and see fireworks.
ps. The drug not working is not going to be the reason if this stock fails. You and I both know that. Let's get em.
Yes. I saw this and just need to show the world the 720, and we will be more than fine. I like the poster who wanted to run a study of rheumatoid arthritis patients who took buccilame and the number who caught covid.
ok. I see your point now. Revive did not fail the pcr test; they just wanted to use it as a measure, but FDA said to try something else. Then your comment about a vague PR becomes more clear. A strongly worded, yet accurate retelling, could have had an entirely different spin on this event. In the long run, it doesn't matter. The stuff works and we get approved, or I am going to live in Nosnibor's basement.
I hope they don't make Michael Frank ask each person how many tissues they used to stop their runny nose as an endpoint.
ps. Let's get em.
As was reported by dales, the fdas ""denial"" and request for dialogue has NOTHING to do with the veracity of the data, but rather is merely a procedural obstacle.
---Yes, This has nothing to do with the data, and the fact that this trial was not shut down has to prove that efficacy is there, and they need to look at a larger sample size. This appears to not be a cause of worry for us longs.
The question I still am a little fuzzy on, albeit probably thinking more clearly than Tua Tagovailoa, is MF, our head coach, advised by the three doctors I mentioned in a prior post, already met with the FDA and decided that the pcr test would be a good endpoint. What changed? Were they looking for a higher percentage than we got on the test, but still see another path to EUA?
GLTA.